Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Guardant Health, Inc. GH
$26.59
-$0.51 (-1.92%)
На 18:01, 12 мая 2023
+237.72%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2799318600.00000000
-
week52high
62.75
-
week52low
20.67
-
Revenue
449538000
-
P/E TTM
-4
-
Beta
0.81365800
-
EPS
-6.57000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | 25 авг 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 08 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 08 авг 2022 г. |
| Piper Sandler | Overweight | 03 июн 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 09 мая 2022 г. |
| Stephens & Co. | Overweight | 06 окт 2022 г. | |
| Craig-Hallum | Buy | 19 окт 2022 г. | |
| Goldman Sachs | Buy | Buy | 04 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 04 ноя 2022 г. |
| Piper Sandler | Neutral | Overweight | 01 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 18 ноя 2022 г. |
| Stephens & Co. | Overweight | Overweight | 07 ноя 2022 г. |
| Scotiabank | Sector Outperform | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bell Michael Brian | D | 6617 | 3309 | 15 янв 2023 г. |
| Bell Michael Brian | D | 4051 | 1320 | 15 янв 2023 г. |
| Bell Michael Brian | A | 5371 | 3309 | 15 янв 2023 г. |
| POTTER MYRTLE S | D | 2258 | 68 | 15 янв 2023 г. |
| POTTER MYRTLE S | A | 1025 | 68 | 15 янв 2023 г. |
| Kalia Kumud | D | 5376 | 5375 | 07 янв 2023 г. |
| Kalia Kumud | D | 23680 | 2187 | 07 янв 2023 г. |
| Kalia Kumud | A | 25867 | 5375 | 07 янв 2023 г. |
| Joyce Meghan V. | D | 2057 | 67 | 04 янв 2023 г. |
| Joyce Meghan V. | A | 1128 | 67 | 04 янв 2023 г. |
Новостная лента
Guardant Health, Inc. (GH) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 23:38
Guardant Health, Inc. (NASDAQ:GH ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Kleban - Vice President-Investor Relations Helmy Eltoukhy - Chairman & Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Craig Eagle - Chief Medical Officer Conference Call Participants Dan Arias - Stifel Puneet Souda - SVB Securities Jack Meehan - Nephron Research Kyle Mikson - Canaccord Julia Qin - JPMorgan Dave Delahunt - Golden Sachs. Mark Massaro - BTIG Tejas Savant - Morgan Stanley Operator Hello, and welcome to the Guardant Health First Quarter 2023 Financial Results Call.
Guardant Health: On Hold For Now
Seeking Alpha
20 апр 2023 г. в 19:57
Shares of liquid biopsy genetic profiling test developer Guardant Health, Inc. have cratered 85% since achieving their all-time high of $181.07 in February 2021. Slowing top line growth, a very long timeline to profitability that includes a significant cash burn, and disappointing (versus expectations) data regarding its Shield colorectal test are to blame.
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
Business Wire
19 апр 2023 г. в 16:05
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com.
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
Business Wire
11 апр 2023 г. в 08:05
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida.
Here's Why Guardant Health (GH) Looks Ripe for Bottom Fishing
Zacks Investment Research
27 мар 2023 г. в 11:26
Guardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.